Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 open label study to evaluate the dose, safety and tolerability of an IP
α-emitting radionuclide therapy (Radspherin®) in subjects with peritoneal carcinomatosis (PC)
from colorectal carcinoma following complete CRS (cytoreduction score CC-0) and HIPEC.
The study consists of three different cohorts:
- Dose escalation cohorts (Phase 1a)
- Repeated injection cohorts (Phase 1b)
- Expansion cohort